Adding Winrevair to standard pulmonary arterial hypertension (PAH) treatment is generally safe and effective, a pooled trial ...

MannKind’s future hinges on Tyvaso DPI's growth, R&D prospects, and financial stability despite competition and risks.

Q4 2024 Earnings Call Transcript February 26, 2025 United Therapeutics Corporation beats earnings expectations. Reported EPS ...

Reports Q4 revenue $735.9M, consensus $734.74M. “I want to congratulate every Unitherian for their relentless dedication, which has allowed us ...

Liquidia Corp. faced setbacks in 2024 due to FDA's backdated exclusivity grant to United Therapeutics, delaying YUTREPIA's launch until May 2025. YUTREPIA's superior clinical trial results and ...